600572.SS
Zhejiang CONBA Pharmaceutical Co.,Ltd. [600572.SS] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
600572.SS Stock Summary
Top 10 Correlated Stocks
600572.SS
In the News
600572.SS Financial details
Company Rating
Buy
Market Cap
12.66B
Income
752.01M
Revenue
6.7B
Book val./share
2.77
Cash/share
0.86
Dividend
0.15
Dividend %
3.06%
Employees
8.42K
Optionable
No
Shortable
Yes
Earnings
20 Apr 2024
P/E
16.75
Forward P/E
-
PEG
-2.66
P/S
1.8
P/B
1.77
P/C
5.84
P/FCF
16.87
Quick Ratio
1.46
Current Ratio
1.94
Debt / Equity
0.08
LT Debt / Equity
0.04
-
-
EPS (TTM)
0.29
EPS next Y
-
EPS next Q
-
EPS this Y
-82.28%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-14.7%
Revenue last 5Y
-2.43%
Revenue Q/Q
-13.11%
EPS Q/Q
-53.77%
-
-
-
-
SMA20
-
SMA50
10.2%
SMA100
-5.15%
Inst Own
-
Inst Trans
-
ROA
7%
ROE
11%
ROC
0.12%
Gross Margin
59%
Oper. Margin
15%
Profit Margin
11%
Payout
60%
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
4.07-7.44
52W High
-28.29%
52W Low
+25.5%
RSI
57.84
Rel Volume
0.7
Avg Volume
36.47M
Volume
25.59M
Perf Week
2.24%
Perf Month
3.29%
Perf Quarter
3.93%
Perf Half Y
-4.56%
-
-
-
-
Beta
0.462
-
-
Volatility
0.06%, 0.08%
Prev Close
0%
Price
5.02
Change
-0.79%
600572.SS Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
| Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 2.58 | 2.55 | 2.35 | 2.39 | 2.33 | |
| Net income per share | 0.31 | -0.1 | 0.18 | 0.78 | 0.14 | |
| Operating cash flow per share | 0.21 | 0.35 | 0.5 | 0.35 | 0.45 | |
| Free cash flow per share | 0.06 | 0.25 | 0.31 | 0.13 | 0.34 | |
| Cash per share | 0.62 | 0.64 | 0.63 | 0.95 | 0.97 | |
| Book value per share | 2.15 | 1.75 | 2 | 2.75 | 2.69 | |
| Tangible book value per share | 1.68 | 1.62 | 1.91 | 2.68 | 2.63 | |
| Share holders equity per share | 2.15 | 1.75 | 2 | 2.75 | 2.69 | |
| Interest debt per share | 1 | 1.07 | 0.99 | 0.61 | 0.48 | |
| Market cap | 15.51B | 16.35B | 11.86B | 12.85B | 12.16B | |
| Enterprise value | 16.48B | 17.34B | 12.65B | 11.85B | 10.89B | |
| P/E ratio | 19.3 | -60.22 | 26.17 | 6.37 | 33.95 | |
| Price to sales ratio | 2.29 | 2.42 | 2.01 | 2.09 | 2.03 | |
| POCF ratio | 28.43 | 17.67 | 9.49 | 14.44 | 10.52 | |
| PFCF ratio | 93.38 | 24.9 | 15.03 | 39.96 | 14.07 | |
| P/B Ratio | 2.75 | 3.51 | 2.36 | 1.82 | 1.76 | |
| PTB ratio | 2.75 | 3.51 | 2.36 | 1.82 | 1.76 | |
| EV to sales | 2.43 | 2.56 | 2.14 | 1.93 | 1.81 | |
| Enterprise value over EBITDA | 11.67 | 14.3 | 9.22 | 3.16 | 9.4 | |
| EV to operating cash flow | 30.19 | 18.74 | 10.12 | 13.32 | 9.42 | |
| EV to free cash flow | 99.17 | 26.41 | 16.02 | 36.85 | 12.6 | |
| Earnings yield | 0.05 | -0.02 | 0.04 | 0.16 | 0.03 | |
| Free cash flow yield | 0.01 | 0.04 | 0.07 | 0.03 | 0.07 | |
| Debt to equity | 0.45 | 0.58 | 0.47 | 0.21 | 0.17 | |
| Debt to assets | 0.24 | 0.27 | 0.25 | 0.14 | 0.11 | |
| Net debt to EBITDA | 0.68 | 0.82 | 0.57 | -0.27 | -1.1 | |
| Current ratio | 1.34 | 1.12 | 1.27 | 1.74 | 1.93 | |
| Interest coverage | 10.82 | 6.29 | 8.94 | 47.6 | 17.79 | |
| Income quality | 0.68 | -3.41 | 2.28 | 0.42 | 2.51 | |
| Dividend Yield | 0.03 | 0.03 | 0.01 | 0.01 | 0.04 | |
| Payout ratio | 0.6 | -1.91 | 0.32 | 0.04 | 1.37 | |
| Sales general and administrative to revenue | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | |
| Research and developement to revenue | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | |
| Intangibles to total assets | 0.13 | 0.06 | 0.06 | 0.05 | 0.05 | |
| Capex to operating cash flow | -0.7 | -0.29 | -0.37 | -0.64 | -0.25 | |
| Capex to revenue | -0.06 | -0.04 | -0.08 | -0.09 | -0.05 | |
| Capex to depreciation | -1.58 | -1.03 | -1.73 | -2.05 | -1.05 | |
| Stock based compensation to revenue | 0 | 0 | 0.01 | 0 | 0 | |
| Graham number | 3.84 | 2.01 | 2.84 | 6.97 | 2.9 | |
| ROIC | 0.1 | 0.7 | 0.11 | 0.34 | 0.08 | |
| Return on tangible assets | 0.09 | -0.03 | 0.05 | 0.2 | 0.03 | |
| Graham Net | -0.47 | -0.47 | -0.29 | 0.29 | 0.3 | |
| Working capital | 1.21B | 502.34M | 884.71M | 2.17B | 2.61B | |
| Tangible asset value | 4.41B | 4.32B | 4.8B | 6.88B | 6.75B | |
| Net current asset value | -166.64M | -120.04M | 208.35M | 1.71B | 1.79B | |
| Invested capital | 0.45 | 0.58 | 0.47 | 0.21 | 0.17 | |
| Average receivables | 1.67B | 1.86B | 1.65B | 1.6B | 1.71B | |
| Average payables | 363.06M | 377.07M | 368.83M | 402.37M | 540.08M | |
| Average inventory | 1.04B | 1.22B | 1.12B | 942.43M | 1.03B | |
| Days sales outstanding | 104.62 | 95.43 | 94.86 | 98.27 | 107.47 | |
| Days payables outstanding | 86.98 | 82 | 63.21 | 75.19 | 94.02 | |
| Days of inventory on hand | 273.31 | 272.02 | 171.81 | 153.93 | 168.55 | |
| Receivables turnover | 3.49 | 3.82 | 3.85 | 3.71 | 3.4 | |
| Payables turnover | 4.2 | 4.45 | 5.77 | 4.85 | 3.88 | |
| Inventory turnover | 1.34 | 1.34 | 2.12 | 2.37 | 2.17 | |
| ROE | 0.14 | -0.06 | 0.09 | 0.29 | 0.05 | |
| Capex per share | -0.14 | -0.1 | -0.18 | -0.22 | -0.11 |
Quarterly Fundamentals Overview
Last date of statement is 2023-09-30 for Q3
| Metric | History | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0.65 | 0.59 | 0.83 | 0.64 | 0.55 | |
| Net income per share | 0.02 | 0.05 | 0.11 | 0.09 | 0.04 | |
| Operating cash flow per share | 0.02 | 0.05 | 0.11 | 0.14 | 0.09 | |
| Free cash flow per share | -0.01 | 0 | 0.09 | 0.12 | 0.06 | |
| Cash per share | 0.74 | 0.97 | 0.94 | 0.97 | 0.86 | |
| Book value per share | 2.67 | 2.69 | 2.79 | 2.73 | 2.77 | |
| Tangible book value per share | 2.61 | 2.63 | 2.74 | 2.65 | 2.7 | |
| Share holders equity per share | 2.67 | 2.69 | 2.79 | 2.73 | 2.77 | |
| Interest debt per share | 0.49 | 0.47 | 0.64 | 0.52 | 0.24 | |
| Market cap | 10.05B | 12.16B | 15.29B | 17.6B | 14.52B | |
| Enterprise value | 9.38B | 10.89B | 14.5B | 16.4B | 12.88B | |
| P/E ratio | 52.21 | 23.6 | 13.45 | 18.98 | 33.89 | |
| Price to sales ratio | 6.12 | 8.04 | 7.18 | 10.77 | 10.23 | |
| POCF ratio | 208.84 | 94.4 | 53.8 | 49.43 | 66.19 | |
| PFCF ratio | -525.11 | -2.77K | 64.22 | 55.27 | 89.79 | |
| P/B Ratio | 1.48 | 1.76 | 2.13 | 2.51 | 2.04 | |
| PTB ratio | 1.48 | 1.76 | 2.13 | 2.51 | 2.04 | |
| EV to sales | 5.71 | 7.2 | 6.81 | 10.04 | 9.07 | |
| Enterprise value over EBITDA | 44.76 | 65.14 | 34.01 | 57.21 | 70.06 | |
| EV to operating cash flow | 194.97 | 84.53 | 51.03 | 46.05 | 58.7 | |
| EV to free cash flow | -490.23 | -2.48K | 60.92 | 51.49 | 79.64 | |
| Earnings yield | 0 | 0.01 | 0.02 | 0.01 | 0.01 | |
| Free cash flow yield | 0 | 0 | 0.02 | 0.02 | 0.01 | |
| Debt to equity | 0.18 | 0.17 | 0.23 | 0.19 | 0.08 | |
| Debt to assets | 0.12 | 0.11 | 0.14 | 0.12 | 0.05 | |
| Net debt to EBITDA | -3.18 | -7.61 | -1.85 | -4.2 | -8.94 | |
| Current ratio | 1.72 | 1.93 | 1.76 | 1.76 | 1.94 | |
| Interest coverage | 22.44 | 17.76 | 30.33 | 29.29 | 15.76 | |
| Income quality | 1 | 1 | 1 | 1.54 | 2.05 | |
| Dividend Yield | 0 | 0 | 0 | 0.02 | 0 | |
| Payout ratio | 0.33 | 0.32 | 0.04 | 1.7 | 0.08 | |
| Sales general and administrative to revenue | 0.2 | -0.17 | 0.06 | -0.05 | 0.24 | |
| Research and developement to revenue | 0.03 | 0.03 | 0.02 | 0.03 | 0.05 | |
| Intangibles to total assets | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 | |
| Capex to operating cash flow | -1.4 | -1.03 | -0.16 | -0.11 | -0.26 | |
| Capex to revenue | -0.04 | -0.09 | -0.02 | -0.02 | -0.04 | |
| Capex to depreciation | -0.86 | -1.7 | -0.58 | -0.47 | 0.38 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0.01 | -0.01 | |
| Graham number | 1.07 | 1.74 | 2.64 | 2.35 | 1.61 | |
| ROIC | 0.02 | 0.02 | 0.04 | 0.03 | 0.02 | |
| Return on tangible assets | 0 | 0.01 | 0.03 | 0.02 | 0.01 | |
| Graham Net | 0.22 | 0.3 | 0.19 | 0.23 | 0.3 | |
| Working capital | 2.12B | 2.61B | 2.52B | 2.54B | 2.74B | |
| Tangible asset value | 6.62B | 6.75B | 7.03B | 6.82B | 6.95B | |
| Net current asset value | 1.65B | 1.79B | 1.67B | 1.77B | 2.01B | |
| Invested capital | 0.18 | 0.17 | 0.23 | 0.19 | 0.08 | |
| Average receivables | 2B | 1.94B | 1.98B | 2.17B | 2.1B | |
| Average payables | 438.81M | 579.64M | 649.69M | 664.07M | 746.99M | |
| Average inventory | 1.03B | 1.1B | 1.15B | 1.18B | 1.24B | |
| Days sales outstanding | 115.35 | 105.15 | 92.61 | 117.8 | 130.46 | |
| Days payables outstanding | 65.19 | 78.54 | 82.28 | 87.58 | 123.98 | |
| Days of inventory on hand | 131.14 | 140.8 | 144.86 | 156.36 | 194.84 | |
| Receivables turnover | 0.78 | 0.86 | 0.97 | 0.76 | 0.69 | |
| Payables turnover | 1.38 | 1.15 | 1.09 | 1.03 | 0.73 | |
| Inventory turnover | 0.69 | 0.64 | 0.62 | 0.58 | 0.46 | |
| ROE | 0.01 | 0.02 | 0.04 | 0.03 | 0.02 | |
| Capex per share | -0.03 | -0.05 | -0.02 | -0.01 | -0.02 |
600572.SS Frequently Asked Questions
What is Zhejiang CONBA Pharmaceutical Co.,Ltd. stock symbol ?
Zhejiang CONBA Pharmaceutical Co.,Ltd. is a CN stock and trading under the symbol 600572.SS
What is Zhejiang CONBA Pharmaceutical Co.,Ltd. stock quote today ?
Zhejiang CONBA Pharmaceutical Co.,Ltd. stock price is $5.02 today.
Is Zhejiang CONBA Pharmaceutical Co.,Ltd. stock public?
Yes, Zhejiang CONBA Pharmaceutical Co.,Ltd. is a publicly traded company.
Company Profile
- Volume Average 36.47M
- Market Capitalization 12.66B
- Employee 8.42K
- CEO Mr. Guoliang Luo
- Headquarters Hangzhou,CN
- IPO Date 2004-04-12
-
Website
https://www.conbagroup.com 
Zhejiang CONBA Pharmaceutical Co.,Ltd. engages in the research and development, production, and sale of traditional Chinese medicines and botanical products in China. It offers chemical medicines, Chinese patent medicines, eye health products, nutritional supplements, health supplies, healthy daily necessities and food products, and other personal care products. The company was formerly known as Lanxi Yunshan Pharmaceutical Factory and changed its name to Zhejiang CONBA Pharmaceutical Co.,Ltd. in October 1999. Zhejiang CONBA Pharmaceutical Co.,Ltd. was founded in 1969 and is headquartered in Hangzhou, China. Zhejiang CONBA Pharmaceutical Co.,Ltd. is a subsidiary of Zhejiang Traditional Chinese Medicine Health Industry Group Co., Ltd.
